| Oral Anticoagulants for Atrial Fibrillation Patients with Active Cancer |
|
Kim, Do Young
(Division of Cardiac Electrophysiology, Korea University Cardiovascular Center, Korea University Guro Hospital)
Lim, Hong Euy (Division of Cardiac Electrophysiology, Korea University Cardiovascular Center, Korea University Guro Hospital) |
| 1 | Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 2014;63:945-53. DOI |
| 2 | Conen D, Wong JA, Sandhu RK, et al. Risk of malignant cancer among women with new-onset atrial fibrillation. JAMA Cardiol 2016;1:389-96. DOI |
| 3 | Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood 2013;122:2310-7. DOI |
| 4 | Lee YJ, Park JK, Uhm JS, et al. Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol 2016;203:372-8. DOI |
| 5 | Kim K, Lee YJ, Kim TH, et al. Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer. Korean Circ J 2018;48:406-17. DOI |
| 6 | Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 2014;19:82-93. DOI |
| 7 | Hendrie PC, Garcia DA. Are new oral anticoagulants ready for use in patients with cancer? J Natl Compr Canc Netw 2013;11:1446-9. DOI |
| 8 | Senoo K, Lane D, Lip GY. Stroke and bleeding risk in atrial fibrillation. Korean Circ J 2014;44:281-90. DOI |
 |
Korea Institute of Science and Technology Information
Gwahangno, Yuseong-gu, Daejeon, 305-806, Korea TEL : +82-42-869-1752
Copyright (c) 2009 KISTI. All Rights Reserved. For more information mail to
webmaster
